VivoSeq
Oncology

Myeloid Malignancy

3

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Myeloid Malignancy is an early-stage landscape with 3 programs across 2 companies. The most active players are BeOne Medicines, Roche.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

2 programs

Phase 1Roche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

BG-75202

BeOne Medicines

Hypomethylation Agent (HMA)

BeOne Medicines

GTB-360

Masonic Cancer Center, University of Minnesota

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Unknown status1 · 17%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Recruiting·PPeking University People's Hospital·Phase 2·NCT06130579·35 enrolled
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
Recruiting·BBeOne Medicines·Phase 1·NCT07619287·118 enrolled
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT06594445·45 enrolled
Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation
Recruiting·UUniversity of Rochester·Preclinical·NCT07263074·120 enrolled
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Terminated·Roche logoRoche·Phase 4·NCT02624141·10 enrolled
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT03873311·114 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)